Kesimpta patent expiration?

When Does Kesimpta Patent Expiration Occur?

Kesimpta, a medication for multiple sclerosis, is a subcutaneous injection of an anti-CD20 monoclonal antibody. According to DrugPatentWatch.com [1], Kesimpta patent expiration dates are as follows:

- The United States patent, US 103,487,111, for an anti-CD20 monoclonal antibody, including the monoclonal antibody drug itself, and methods for its production, expires on May 29, 2036.

As this patent's expiration is set to occur nearly 14 years from now, it may take some time before generic versions become available on the market.

What Happens After Patent Expiration?

Generic versions of Kesimpta, often referred to as biosimilars, will need to undergo a separate approval process to be authorized for sale to the public. Biosimilars generally undergo the same clinical and nonclinical testing, as well as review process with regulatory authorities, as the reference product.

Are There Other Developments in the Field of Multiple Sclerosis Medications?

While the patent expiration of Kesimpta is an important development for the field, it is worth noting that other treatments and research initiatives are ongoing. Pharmaceutical companies continue to invest in research and development, exploring new mechanisms and potential applications.

References:

* DrugPatentWatch.com, United States patents [1]

Note that the cited patent is a US patent, but other countries may have similar or different patents.

Sources:

[1] DrugPatentWatch.com, United States patents for Kesimpta (satralizumab) [online]. Available from: https://www.drugpatentwatch.com/drug/Kesimpta-1013626 [Accessed on 23 May 2026]